RIGEL PHARMACEUTICALS INC (RIGL) earnings date
Mar 2, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 67% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 36 days, typically, give or take 12 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Thu, Nov 5, 2026 | after close | 36 | 8-K |
| Q2 FY2026 | Tue, Aug 4, 2026 | after close | 35 | 8-K |
| Q1 FY2026 | Tue, May 5, 2026 | after close | 35 | 8-K |
| Q4 FY2025 | Tue, Mar 3, 2026 | after close | 62 | 8-K |
| Q3 FY2025 | Tue, Nov 4, 2025 | after close | 35 | 8-K |
| Q2 FY2025 | Tue, Aug 5, 2025 | after close | 36 | 8-K |
| Q1 FY2025 | Tue, May 6, 2025 | after close | 36 | 8-K |
| Q4 FY2024 | Tue, Mar 4, 2025 | after close | 63 | 8-K |
What they guided beta
| Q3 FY2026 | "The Phase 1b study of R289, Rigel’s dual IRAK1/4 inhibitor, in patients with lower-risk MDS is ongoing and Rigel expects to select the recommended Phase 2 dose by the end of 2026" exhibit |
| Q3 FY2026 | "Rigel continues to advance its Phase 1b clinical study of R289 1 , a potent and selective dual inhibitor of interleukin receptor-associated kinases 1 and 4 (IRAK1/4), in patients with relapsed or refractory (R/R) lower-risk myelodysplastic syndrome (MDS) and the company expects to complete enrollment and select the recommended Phase 2 dose for future development by the end of 2026." exhibit |
| Q3 FY2026 | "Cash, cash equivalents and short-term investments as of September 30, 2026 was $99.3 million , compared to $155.0 million as of December 31, 2025 . 2026 Outlook Rigel has updated its 2026 total revenues guidance to approximately $290 to $295 million, from the previous range of approximately $285 to $295 million, which includes:" exhibit |
| Q3 FY2026 | "The company also continues to anticipate it will report positive net income for the full year 2026, while funding existing and new clinical development programs." exhibit |
| Q3 FY2026 | "The American Cancer Society estimates that there will be about 22,720 new cases in the United States, most in adults, in 2026. 2 Relapsed AML affects about half of all patients who, following treatment and remission, experience a return of leukemia cells in the bone marrow. 3,4 Refractory AML, which affects between 10 and 40 percent of newly diagnosed patients, occurs when a patient fails to achieve remission even after intensive treatment. 5 Quality of life declines for patients with each successive line of treatment for AML, and well-tolerated treatments in relapsed or refractory disease rem" exhibit |
| Q2 FY2026 | "Advanced R289 development program; Phase 1b study in patients with lower-risk MDS remains on track to complete enrollment in the dose expansion portion and select the recommended Phase 2 dose in the second half of 2026" exhibit |
| Q2 FY2026 | "Conference call and webcast scheduled today at 4:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif., August 4, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today reported financial results for the second quarter ended June 30, 2026 , including sales of TAVALISSE ® (fostamatinib disodium hexahydrate), GAVRETO ® (pralsetinib) and REZLIDHIA ® (olutasidenib), and recent business progress, including the in-license of VEPPANU TM (vepdegestrant), a PRoteolysis TArgeting Chimera (PROTAC)." exhibit |
| Q2 FY2026 | "“We are also advancing the development of R289 in our ongoing Phase 1b study in patients with R/R lower-risk MDS, and remain on track to complete enrollment in the dose expansion phase of the study, select a recommended Phase 2 dose in the second half of 2026 and share preliminary data by year end.”" exhibit |
| Q2 FY2026 | "Upon close of the transaction, Rigel immediately initiated launch activities and expects VEPPANU to be commercially available in the United States for the treatment of second line-plus (2L+) ER+/HER2-, ESR1 -mutated mBC in mid-August 2026." exhibit |
| Q2 FY2026 | "Rigel continues to advance its Phase 1b clinical study of R289 1 , a potent and selective dual inhibitor of interleukin receptor-associated kinases 1 and 4 (IRAK1/4), in patients with relapsed or refractory (R/R) lower-risk myelodysplastic syndrome (MDS), with enrollment in the dose expansion phase ongoing and on track to be completed in the second half of 2026." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/RIGL
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/RIGL
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/RIGL/"><img src="https://veritasdata.dev/embed/RIGL.svg" alt="RIGL earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/RIGL/)
Script
<script async src="https://veritasdata.dev/embed/RIGL.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/RIGL"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.